Editorial
According to Barcelona clinic liver cancer (BCLC) staging and treatment allocation system, chemoembolization is recommended as the first-line treatment for intermediate-stage hepatocellular carcinoma (HCC) and sorafenib for advanced-stage HCC. 1 3 However, all of them were retrospective in the study design.
In the current issue, Lee et al. conducted a retrospective study comparing surgical resection and chemoembolization with additional radiotherapy in patients with HCC with portal vein invasion. 4 They compared the survival outcome of 43 patients who underwent surgical resection for HCC with portal vein invasion without previous treatment with that of another 43 patients who received chemoembolization followed by radiotherapy as initial treatment. Both groups were matched for Child-Pugh class, tumor size, and extent of portal vein invasion. And, they demonstrated that the cumulative overall survival was significantly longer in patients treated with resection than in those treated with chemoembolization followed by radiotherapy, and surgical resection was an independent predictive factor for better survival outcome on multivariate analysis. However, because of major problem in the study design, it is difficult to agree with the results of this study. In the resection group, the authors excluded the patients with resection margin involvement and incomplete tumor removal. It means that the
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Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion patients with "surgically resectable" HCC on initial evaluation were screened and patients who underwent "curative resection" were finally selected. As a result, the survival outcome of resection group was extremely good. For fair comparison, the same selection criteria should be applied to chemoembolization plus radiotherapy group. However, unfortunately, it is impossible to do so. In order to solve this problem, the authors should include patients with "surgically resectable" HCC regardless of resection margin involvement and incomplete tumor removal in the resection group and exclude patients with "surgically unresectable" HCC from chemoembolization plus radiotherapy group. Matching with Child-Pugh class, tumor size, and extent of portal vein invasion was not enough. Even after matching, the survival outcome of chemoembolization plus radiotherapy in this study was almost same with that of their previous reports. 5, 6 In determining resectability of HCC, we should consider performance status, hepatic functional reserve, degree of portal hypertension, tumor distribution (localized, unilobar, bilobar), tumor location (central, peripheral), and intrahepatic metastasis as the authors partly pointed out in the discussion section. Those factors should be included in the selection criteria and/or matching process. I agree with the facts that intermediate and advanced HCCs are really diverse and, therefore, subclassification is needed. There is a chance that more aggressive therapies including hepatic resection may reveal better survival outcome in the favorable subgroups than standard therapies. Because of difficulties conducting prospective randomized trials in HCC, I believe it is still valuable to continue our efforts to find out the subgroups in which hepatic resection shows better outcome than standard therapies from our routine practice cohort. However, for validity of retrospective studies comparing hepatic resection with standard therapies in advanced HCCs, every effort should be made to eliminate or minimize the preexisting huge selection bias because hepatic resection is almost always selected in patients with good hepatic functional reserve, good performance status, no co-morbidities, and localized tumors.
